MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Kura Oncology Inc

Open

SectorGezondheidszorg

9.98 4.83

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

9.42

Max

10.38

Belangrijke statistieken

By Trading Economics

Inkomsten

-8.7M

-66M

Verkoop

1.2M

15M

Winstmarge

-432.509

Werknemers

192

EBITDA

-8M

-73M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+175.72% upside

Dividenden

By Dow Jones

Volgende Winsten

6 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

238M

786M

Vorige openingsprijs

5.15

Vorige sluitingsprijs

9.98

Nieuwssentiment

By Acuity

40%

60%

161 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Kura Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 okt 2025, 16:58 UTC

Winsten

BMW Trims 2025 View, Citing Weaker Performance in China

7 okt 2025, 23:43 UTC

Marktinformatie

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 okt 2025, 23:36 UTC

Marktinformatie

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 okt 2025, 23:19 UTC

Marktinformatie

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 okt 2025, 22:50 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 okt 2025, 22:50 UTC

Marktinformatie

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 okt 2025, 22:40 UTC

Marktinformatie

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 okt 2025, 21:56 UTC

Marktinformatie

Global Equities Roundup: Market Talk

7 okt 2025, 21:56 UTC

Marktinformatie

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

7 okt 2025, 20:44 UTC

Populaire aandelen

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 okt 2025, 19:42 UTC

Marktinformatie

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 okt 2025, 19:23 UTC

Acquisities, Fusies, Overnames

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 okt 2025, 19:07 UTC

Marktinformatie

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 okt 2025, 19:02 UTC

Marktinformatie

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 okt 2025, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

7 okt 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

7 okt 2025, 16:20 UTC

Marktinformatie

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 okt 2025, 16:15 UTC

Marktinformatie

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 okt 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

7 okt 2025, 15:37 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 okt 2025, 15:37 UTC

Marktinformatie

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 okt 2025, 15:33 UTC

Marktinformatie

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 okt 2025, 15:25 UTC

Marktinformatie

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 okt 2025, 15:15 UTC

Marktinformatie

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 okt 2025, 15:04 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

7 okt 2025, 15:04 UTC

Marktinformatie

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 okt 2025, 14:56 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 okt 2025, 14:56 UTC

Marktinformatie

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 okt 2025, 14:52 UTC

Winsten

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Peer Vergelijking

Prijswijziging

Kura Oncology Inc Prognose

Koersdoel

By TipRanks

175.72% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 26 USD  175.72%

Hoogste 40 USD

Laagste 11 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kura Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

11

Buy

2

Hold

0

Sell

Technische score

By Trading Central

5.575 / 6.6Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

161 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.
help-icon Live chat